Results 161 to 170 of about 26,835 (181)

Vemurafenib

Reactions Weekly, 2019
  +4 more sources

Vemurafenib

Reactions Weekly, 2021
openaire   +1 more source

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2020
Ralf Gutzmer, Daniil Stroyakovskiy, Helen Gogas   +2 more
exaly  

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations

Annals of Oncology, 2020
Julien Mazieres
exaly  

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

New England Journal of Medicine, 2011
Paul B Chapman, Caroline Robert, James Larkin   +2 more
exaly  

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

New England Journal of Medicine, 2012
Kevin B Kim, Grant A Mcarthur, Thomas E Hutson   +2 more
exaly  

Time for adjuvant vemurafenib?

Nature Reviews Clinical Oncology, 2018
Diana Romero
exaly  

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study

Annals of Oncology, 2017
Claus Garbe, Dirk Schadendorf
exaly  

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Lancet Oncology, The, 2018
Reinhard Dummer, Paolo A Ascierto, Ana Arance   +2 more
exaly  

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Lancet Oncology, The, 2016
Paolo A Ascierto, Victoria Atkinson, Anna Maria Di Giacomo   +2 more
exaly